2001 Author Index

Note: (ab) represents abstract

A

Aarsvold, JN, 1512(ab), 1525(ab)
Aburano, T, 1579(ab)
Adams, KH, 1561(ab)
Adler, LP, 1582(ab)
Afriyie, MO, 1515(ab), 1581(ab)
Agerskov, L, 1575(ab)
Ahlberg, A, 1501(ab), 1551(ab)
Alavi, A, 1564(ab)
Allman, KC, 1506(ab)
Alonso, O, 152, 1519(ab)
Al-Saeed, T, 1567(ab)
Amin, K, 30
Anliker, MR, 1604(ab)
Anstett, F, 1504(ab)
Aoun, G, 1501(ab)
Armbrust-Henrich, H, 1508(ab)
Armstrong, J, 1502(ab)
Arroyo, AJ, 1528(ab)
Assaei, R, 1558(ab), 1559(ab)

B

Baehre, M, 1580(ab), 1584(ab)
Bakker, H, 1570(ab)
Bander, NH, 1521(ab)
Barrow, SA, 1560(ab), 1563(ab)
Bartenstein, P, 1508(ab)
Beretta, M, 1519(ab)
Berthold, T, 1522(ab)
Bhargava, KK, 1515(ab)
Bitner, SJ, 197
Blumenfeld, H, 1562(ab)
Boerman, O, 1570(ab)
Bohuslavizki, KH, 50
Bolus, NE, 67, 143
Bonab, AA, 1563(ab)
Borges-Neto, S, 1503(ab)
Brake, SE, 197
Bray, DM, 1586(ab)
Brinkbaeumer, K, 1507(ab), 1514(ab)
Britt, C, 1522(ab)
Brown, ML, 1566(ab)
Bruno, A, 1588(ab)
Bush, V, 1506(ab)
Bybel, B, 30

C

Carlson, KC, 1572(ab)
Carr, B, 1566(ab)
Castellani, M, 1588(ab)
Cezar, RB, 1609(ab)
Chandna, H, 183
Chen, CH, 1583(ab)
Clark, JA, 1553(ab)
Clark, M, 1576(ab)
Clarke, M, 136, 172
Clermont, DA, 1553(ab)
Coates, DM, 1523(ab)
Coleman, RE, 1503(ab)
Collins, JA, 154, 1554(ab), 1556(ab), 1557(ab)
Collins, L, 1556(ab)
Connolly, SA, 1560(ab)
Conway, AA, 1504(ab)
Corsi, M, 1562(ab)
Corstens, F, 1565(ab), 1570(ab)
Costedio, J, 1567(ab)
Coulston, CH, 161
Coutinho, B, 1506(ab)
Cservenyak, T, 1522(ab)
Cuklanz, EJ, 53, 202

D

Dalipaj, MM, 1502(ab), 1611(ab)
Das, SK, 1527(ab)
Dawadi, BR, 37
DeGreet, M, 1565(ab)
Delbeke, D, 1518(ab)
Delpassand, E, 1555(ab), 1572(ab)
Derango, A, 1516(ab)
Dodge, RM, 1607.2(ab)
Doggart, MJ, 1611(ab)
Donovan, P, 193
Douglass, SA, 1608(ab)
Dresel, S, 1507(ab), 1514(ab)
Duggan, JE, 1506(ab)
Dyckman, W, 1551(ab)

E

Elgazzar, AH, 1567(ab)
Elkamhawy, AA, 183
Elsaid, M, 1567(ab)
Ennow, K, 1575(ab)
Erwin, WD, 12, 1516(ab)
Espasandin, J, 152

F

Fahey, FH, 1582(ab)
Farrell, M, 1522(ab)
Fearn, C, 1574(ab)
Fielding, HW, 1529(ab)
Fischman, AJ, 1560(ab), 1563(ab)
Fleming, R, 1501(ab)
Fram, D, 1551(ab)
France, M, 1566(ab)
Freeman, J, 1562(ab)
Frodl, GS, 1610(ab)
Fujita, T, 1587(ab)

G

Gansen, DN, 1585(ab)
Gerundini, P, 1588(ab)
Gifford, HC, 1607(ab)
Gladding, RL, 1564(ab)
Goldsmith, SJ, 1521(ab)
Gough, J, 1604(ab), 1607.1(ab)
Graham, MM, 1505(ab), 1552(ab), 1553(ab), 1568(ab)
Grant, SF, 1525(ab)
Grass, MM, 40, 1509(ab)
Griff, M, 1522(ab)
Groch, MW, 12, 1516(ab)

H

Hackett, MT, 189, 1517(ab), 1554(ab), 1556(ab), 1557(ab)
Hahn, K, 1507(ab), 1514(ab)
Halkar, RK, 1513(ab), 1525(ab)
Hammerlund, LA, 1516(ab)
Hanson, MW, 1503(ab)
Harkness, BA, 1, 59, 135, 171, 1582(ab)
Harrison, S, 1501(ab), 1551(ab)
Heidary, A, 1558(ab)
Heller, GV, 1501(ab), 1551(ab)
Hichwa, RD, 1553(ab)
Hnatowich, DJ, 1612(ab)
Hung, JC, 1524(ab), 1571(ab), 1574(ab), 1585(ab), 1610(ab)

I

Ireland, LA, 1505(ab), 1552(ab)
Irvine, P, 1502(ab), 1611(ab)
Ishiguro, M, 1513(ab)
Ishikawa, Y, 1579(ab)
Ishizu, K, 1587(ab)
Itti, E, 1609(ab)
Iverson, BC, 1524(ab), 1571(ab)

J

Jacobson, MS, 1574(ab), 1610(ab)
Jensen, M, 1575(ab)
Johnson, B, 169, 205
Johnson, K, 1607.2(ab)
Johnson, SG, 1511(ab)

K

Kaplen, J, 1589(ab)
Kappas, R, 1576(ab)
Karesh, SM, 1520(ab)
Kashiba, A, 1579(ab)
Katoh, A, 1513(ab)
Kebede, Y, 1602(ab)
Kelly, GT, 1505(ab), 1552
Keppler, JS, 173
Kerchenfaut, KW, 1603(ab)
Kiefer, V, 154, 189, 193
Kikukawa, K, 1513(ab)
Kim, BY, 30
Kim, EE, 1511(ab)
King, LD, 1589(ab)
King, MA, 1607(ab)
Knudsen, GM, 1526(ab), 1561(ab)
Koenders, E, 1570(ab)
Koga, S, 1513(ab)
Kohlhorst, L, 1523(ab)
Kok, PJ, 1565(ab)
Konishi, J, 1587(ab)
Koslowsky, IL, 197
Kostakoglu, L, 1521(ab)
Kruger, RL, 79
Kuji, I, 1521(ab)
Kurdziel, K, 1589(ab)
Kuzniecky, R, 1527(ab)

L

Lago, G, 152
Le, PH, 1606(ab)
Lehmberg, O, 50
Leo, R, 1588(ab)
Leong, LK, 79
Leveque, F, 1581(ab)
Licho, R, 1606(ab), 1607(ab), 1612(ab), 1613(ab)
Lin, HD, 1578(ab), 1583(ab)
Lin, KP, 1578(ab), 1583(ab)
Lincoln, MT, 1506(ab)
Liu, J, 1527(ab)
Liu, K, 1607.1(ab), 1607.2(ab), 1614(ab)
Liu, RS, 1578(ab), 1583(ab)
Livni, E, 1563(ab)
Loutfi, I, 1529(ab)

2001 Author Index

Note: (ab) represents abstract

A

Aarsvold, JN, 1512(ab), 1525(ab)
Aburano, T, 1579(ab)
Adams, KH, 1561(ab)
Adler, LP, 1582(ab)
Afriyie, MO, 1515(ab), 1581(ab)
Agerskov, L, 1575(ab)
Ahlberg, A, 1501(ab), 1551(ab)
Alavi, A, 1564(ab)
Allman, KC, 1506(ab)
Alonso, O, 152, 1519(ab)
Al-Saeed, T, 1567(ab)
Amin, K, 30
Anliker, MR, 1604(ab)
Anstett, F, 1504(ab)
Aoun, G, 1501(ab)
Armbrust-Henrich, H, 1508(ab)
Armstrong, J, 1502(ab)
Arroyo, AJ, 1528(ab)
Assaei, R, 1558(ab), 1559(ab)

B

Baehre, M, 1580(ab), 1584(ab)
Bakker, H, 1570(ab)
Bander, NH, 1521(ab)
Barrow, SA, 1560(ab), 1563(ab)
Bartenstein, P, 1508(ab)
Beretta, M, 1519(ab)
Berthold, T, 1522(ab)
Bhargava, KK, 1515(ab)
Bitner, SJ, 197
Blumenfeld, H, 1562(ab)
Boerman, O, 1570(ab)
Bohuslavizki, KH, 50
Bolus, NE, 67, 143
Bonab, AA, 1563(ab)
Borges-Neto, S, 1503(ab)
Brake, SE, 197
Bray, DM, 1586(ab)
Brinkbaeumer, K, 1507(ab), 1514(ab)
Britt, C, 1522(ab)
Brown, ML, 1566(ab)
Bruno, A, 1588(ab)
Bush, V, 1506(ab)
Bybel, B, 30

C

Carlson, KC, 1572(ab)
Carr, B, 1566(ab)
Castellani, M, 1588(ab)
Cezar, RB, 1609(ab)
Chandna, H, 183
Chen, CH, 1583(ab)
Clark, JA, 1553(ab)
Clark, M, 1576(ab)
Clarke, M, 136, 172
Clermont, DA, 1553(ab)
Coates, DM, 1523(ab)
Coleman, RE, 1503(ab)
Collins, JA, 154, 1554(ab), 1556(ab), 1557(ab)
Collins, L, 1556(ab)
Connolly, SA, 1560(ab)
Conway, AA, 1504(ab)
Corsi, M, 1562(ab)
Corstens, F, 1565(ab), 1570(ab)
Costedio, J, 1567(ab)
Coulston, CH, 161
Coutinho, B, 1506(ab)
Cservenyak, T, 1522(ab)
Cuklanz, EJ, 53, 202

D

Dalipaj, MM, 1502(ab), 1611(ab)
Das, SK, 1527(ab)
Dawadi, BR, 37
DeGreet, M, 1565(ab)
Delbeke, D, 1518(ab)
Delpassand, E, 1555(ab), 1572(ab)
Derango, A, 1516(ab)
Dodge, RM, 1607.2(ab)
Doggart, MJ, 1611(ab)
Donovan, P, 193
Douglass, SA, 1608(ab)
Dresel, S, 1507(ab), 1514(ab)
Duggan, JE, 1506(ab)
Dyckman, W, 1551(ab)

E

Elgazzar, AH, 1567(ab)
Elkamhawy, AA, 183
Elsaid, M, 1567(ab)
Ennow, K, 1575(ab)
Erwin, WD, 12, 1516(ab)
Espasandin, J, 152

F

Fahey, FH, 1582(ab)
Farrell, M, 1522(ab)
Fearn, C, 1574(ab)
Fielding, HW, 1529(ab)
Fischman, AJ, 1560(ab), 1563(ab)
Fleming, R, 1501(ab)
Fram, D, 1551(ab)
France, M, 1566(ab)
Freeman, J, 1562(ab)
Frodl, GS, 1610(ab)
Fujita, T, 1587(ab)

G

Gansen, DN, 1585(ab)
Gerundini, P, 1588(ab)
Gifford, HC, 1607(ab)
Gladding, RL, 1564(ab)
Goldsmith, SJ, 1521(ab)
Gough, J, 1604(ab), 1607.1(ab)
Graham, MM, 1505(ab), 1552(ab), 1553(ab), 1568(ab)
Grant, SF, 1525(ab)
Grass, MM, 40, 1509(ab)
Griff, M, 1522(ab)
Groch, MW, 12, 1516(ab)

H

Hackett, MT, 189, 1517(ab), 1554(ab), 1556(ab), 1557(ab)
Hahn, K, 1507(ab), 1514(ab)
Halkar, RK, 1513(ab), 1525(ab)
Hammerlund, LA, 1516(ab)
Hanson, MW, 1503(ab)
Harkness, BA, 1, 59, 135, 171, 1582(ab)
Harrison, S, 1501(ab), 1551(ab)
Heidary, A, 1558(ab)
Heller, GV, 1501(ab), 1551(ab)
Hichwa, RD, 1553(ab)
Hnatowich, DJ, 1612(ab)
Hung, JC, 1524(ab), 1571(ab), 1574(ab), 1585(ab), 1610(ab)

I

Ireland, LA, 1505(ab), 1552(ab)
Irvine, P, 1502(ab), 1611(ab)
Ishiguro, M, 1513(ab)
Ishikawa, Y, 1579(ab)
Ishizu, K, 1587(ab)
Itti, E, 1609(ab)
Iverson, BC, 1524(ab), 1571(ab)

J

Jacobson, MS, 1574(ab), 1610(ab)
Jensen, M, 1575(ab)
Johnson, B, 169, 205
Johnson, K, 1607.2(ab)
Johnson, SG, 1511(ab)

K

Kaplen, J, 1589(ab)
Kappas, R, 1576(ab)
Karesh, SM, 1520(ab)
Kashiba, A, 1579(ab)
Katoh, A, 1513(ab)
Kebede, Y, 1602(ab)
Kelly, GT, 1505(ab), 1552
Keppler, JS, 173
Kerchenfaut, KW, 1603(ab)
Kiefer, V, 154, 189, 193
Kikukawa, K, 1513(ab)
Kim, BY, 30
Kim, EE, 1511(ab)
King, LD, 1589(ab)
King, MA, 1607(ab)
Knudsen, GM, 1526(ab), 1561(ab)
Koenders, E, 1570(ab)
Koga, S, 1513(ab)
Kohlhorst, L, 1523(ab)
Kok, PJ, 1565(ab)
Konishi, J, 1587(ab)
Koslowsky, IL, 197
Kostakoglu, L, 1521(ab)
Kruger, RL, 79
Kuji, I, 1521(ab)
Kurdziel, K, 1589(ab)
Kuzniecky, R, 1527(ab)

L

Lago, G, 152
Le, PH, 1606(ab)
Lehmberg, O, 50
Leo, R, 1588(ab)
Leong, LK, 79
Leveque, F, 1581(ab)
Licho, R, 1606(ab), 1607(ab), 1612(ab), 1613(ab)
Lin, HD, 1578(ab), 1583(ab)
Lin, KP, 1578(ab), 1583(ab)
Lincoln, MT, 1506(ab)
Liu, J, 1527(ab)
Liu, K, 1607.1(ab), 1607.2(ab), 1614(ab)
Liu, RS, 1578(ab), 1583(ab)
Livni, E, 1563(ab)
Loutfi, I, 1529(ab)

M

MacDonald, J, 32
Madras, BK, 1563(ab)
Madsen, M, 1568(ab)
Maeda, DW, 1571(ab)
Magoun, S, 84
Mahoney, DW, 1571(ab)
Mann, A, 1501(ab), 1551(ab)
Mann, EG, 1612(ab), 1613(ab)
Mar, MV, 1511(ab)
Martin, WH, 1518(ab)
Martinez, M, 152
Martiny, L, 1561(ab)
Matrow, CM, 1607(ab)
Matsumoto, K, 1587(ab)
Mays, TL, 1574(ab)
McCook, B, 1566(ab)
McGill, CC, 1501(ab)
McPherson, JD, 1569(ab), 1572(ab)
Measel, DL, 1512(ab)
Meeuwis, AP, 1565(ab)
Meltzer, P, 1563(ab)
Menda, Y, 1553(ab)
Merani, A, 1611(ab)
Mishkin, FS, 1608(ab), 1609(ab)
Mitchell, B, 84
Moorin, R, 22
Morano, G, 1510(ab), 1562(ab), 1586(ab)
Morgan, E, 1551(ab)
Morgan, MM, 159
Mountz, JM, 1527(ab)
Mut, F, 1519(ab)

N

Namislo, LJ, 1606(ab)
Narayanan, MV, 1607(ab)
Neumann, DR, 30
Neurath, M, 1508(ab)
Niblack, EM, 1509(ab)
Nunez, M, 1519(ab)

O

O'Connor, MK, 79
Ojha, BC, 1527(ab)
Omar, AM, 1567(ab)
Ostroff, R, 1562(ab)
Oyen, WJ, 1565(ab)

P

Pacl, H, 1614(ab)
Pagnanelli, RA, 1503(ab)
Palestro, CJ, 1515(ab), 1581(ab)
Patel, Y, 1528(ab)
Patton, JA, 1518(ab)
Pavlicek, P, 1522(ab)
Pedersen, HS, 1575(ab)
Pepper, R, 1523(ab)
Perez, A, 1510(ab)
Petersen, DW, 1568(ab)
Pham, HL, 1608(ab), 1609(ab)
Pierre, J, 1581(ab)
Pinsky, T, 1528(ab)
Podoloff, D, 1511(ab), 1555(ab), 1573(ab)
Ponto, LL, 1553(ab)
Porter, DV, 1577(ab)
Potter, CB, 1601(ab)
Pretorius, H, 1613(ab)
Primiano, C, 1501(ab)
Prowsner, RA, 1560(ab)
Pugliese, PV, 1515(ab), 1581(ab)

R

Ravin, PD, 1613(ab)
Rezvani, K, 1608(ab)
Rich, T, 30
Richmond, JC, 1553(ab)
Richter, E, 1580(ab), 1584(ab)
Riggert, J, 1568(ab)
Robinson, E, 46
Rosen, J, 1566(ab)
Rothfusz, BC, 1525(ab)
Ruddy, TD, 1502(ab), 1611(ab)

S

Sajdak, RA, 1520(ab)
Sandler, MP, 1518(ab)
Sato, J, 1579(ab)
Sawai, T, 1513(ab)
Schelper, LF, 1580(ab), 1584(ab)
Schiavini, M, 1588(ab)
Schreckenberger, M, 1508(ab)
Schunk, K, 1508(ab)
Schwartz, P, 1510(ab)
Sechrist, S, 86
Seibyl, JP, 1510(ab), 1562(ab), 1586(ab)
Seliger, JD, 1605(ab)
Semaan, H, 1528(ab)
Senda, K, 1513(ab)
Senglaub, TM, 1520(ab)
Seo, I, 1576(ab)
Sheetz, MM, 1566(ab)
Shih, W, 1517(ab)
Shih, W-J, 46, 84, 154, 189, 193
Shirakawa, S, 1513(ab)
Shuke, N, 1579(ab)
Smith, EO, 1510(ab)
Smith, HC, 1582(ab)
Smith-Jones, PM, 1521(ab)
Sörensen, A, 1575(ab)
Spieth, ME, 1604(ab), 1607.1(ab), 1607.2(ab), 1614(ab)
Stachowiak, A, 1573(ab)
Stadalnik, RC, 1524(ab)
Stahr, K, 1561(ab)
Stillwell, DS, 1509(ab)
Sullivan, A, 56, 88
Swanston, NM, 1555(ab)
Sy, W, 1576(ab)

T

Tadamura, E, 1587(ab)
Tanhehco, T, 1562(ab)
Thomas, E, 52, 87, 163, 201
Thompson, MA, 61, 137
Thomsen, G, 1526(ab)
Thomson, LE, 1506(ab)
Timpe, JT, 1572(ab)
Tomas, MB, 1515(ab)1581(ab)
Toulouse, KA, 1524(ab), 1571(ab)
Toyada, H, 1587(ab)
Toyama, H, 1513(ab)
Turkington, TG, 4

U

Uffelman, W, 56, 88, 168, 205
Uranga, AP, 1562(ab)

V

Vallabhajosula, S, 1521(ab)
Varzegar, R, 1558(ab), 1559(ab)
Vehling, D, 1508(ab)
Videbæk, C, 1526(ab)
Vila, R, 1519(ab)
Voltini, F, 1588(ab)
Votaw, D, 1588(ab)

W

Wang, JK, 1583(ab)
Ward, CA, 1553(ab)
Washburn, SA, 1518(ab)
Waterstram-Rich, K, 3, 60
Watkins, GL, 1553(ab)
Weaver, JP, 1606(ab)
Wendt, R, 1555(ab), 1573(ab)
Wierzbinski, RS, 84, 1556(ab), 1557(ab)
Wiseman, GA, 1577(ab), 1585(ab)
Wisniewski, G, 1586(ab)
Withrow, KA, 1607.1(ab)
Worsley, T, 40
Wu, LC, 1578(ab), 1583(ab)

Y

Yokoyama, K, 1513(ab)
Yu, CL, 1578(ab), 1583(ab)

Z

Zachary, RA, 1612(ab)
Zajko, A, 1566(ab)
Zakeri, F, 1558(ab)
Zeng, W, 156
Zhuang, HM, 1564(ab)
Zimmer, AM, 1569(ab), 1572(ab)
Zito, F, 1588(ab)
Zoe, H, 1521(ab)
Zubal, IG, 1562(ab), 1586(ab)

2001 Subject Index

Note: (ab) represents abstract

A

Adenosine
caffeine effects, list of food and drugs containing, 1605(ab)
escalating dose, hyperreactive airway disease, 1552(ab)
stress testing, caffeine effects, 1505(ab)
Artifacts, motion, OSEM and FBP SPECT reconstruction algorithms, 1579(ab)
Attenuation correction
nonuniform and uniform, comparative analysis, PET and SPECT, 1586(ab)
pre and post injection transmission, FDG PET brain studies, 1588(ab)

B

Background equivalent radiation time, communication of, 156
Biodistribution, FDG PET, glucose level, age and fasting effects, 1565(ab)
Biostatistics, epidemiology for the nuclear medicine technologist, 143
Bone-imaging agent
extravasation of, ipsilateral lymph nodes secondary to, 154
localization of ^{99m}Tc HMDP, extraskeletal myxoid chondrosarcoma, 84
Bone scan, pelvic, OSEM reconstruction compared to FBP in, 1513(ab)
Bone scintigraphy
idiopathic uptake of ^{99m}Tc MDP, hepatic, 32
ipsilateral lymph nodes, left hand, 154
Book reviews
Nuclear Hepatology: A Textbook of Hepatobiliary Diseases, 50
Nuclear Medicine Procedure Manual 2000–2002, 86
Brain imaging, SPECT, artifacts with metallic cranioplasty, 189
Breast scintigraphy, miraluma in, adjunct to mammography, 1510(ab)

C

Caffeine
adenosine stress testing and, 1505(ab)
list of foods containing, 1605(ab)
Carbon-11 altropane, PET, dopamine transporter density, striatum, 1563(ab)
Cardiac imaging
acute rest myocardial, impact of coronary flow restoration, 1551(ab)
dipyridamole and adenosine, ^{99m}Tc sestamibi SPECT, 1501(ab)
FDG or ^{99m}Tc, film badge readings in the 90's, 1520(ab)
simultaneous dual isotope, photon energy recovery technique, 1504(ab)
Cause and effect relationships, nuclear medicine, 143
Centralized management, corporate nuclear medicine, 40
Cerebral blood flow, changes, during ECT, ^{99m}Tc HMPAO brain SPECT, 1562(ab)
Certification examination, NMTCB, computerized, 37
Chromosomes, aberrations, peripheral blood lymphocytes, radiation workers in Iran, 1559(ab)
Chylothorax, lymphoscintigraphy in, ^{99m}Tc filtered colloid, 30
Coincidence detection camera
functional anatomical mapping, with indeterminate PET scans, 1517(ab)
ongoing exposure to 511 keV photons, sodium iodide crystal, PET, 1515(ab)
partial volume effect, objects with similar axial diameter, 1581(ab)
thick sodium iodide crystal, performance evaluation, 1516(ab)
Coincidence imaging
diagnosis of hibernating myocardium, 1507(ab)
gamma camera, 1514(ab)
quantitative tumor analysis, FDG PET, 1589(ab)
Collimation, collimators, medium energy, ^{131}I thyroid uptake using gamma camera, 1576(ab)
Cranioplasty, metallic, brain SPECT artifacts with, 189
CT, instrumentation and quality control, in 2001, 12

D

Dopamine transporters, density, striatum, ^{11}C altropane PET, 1563(ab)
Dose calibration, FDG, error dispensing, 1575(ab)
Dosimetry, radiation, monoclonal antibody ^{131}I J591 *versus* ^{90}Y J591, 1521(ab)
Dual isotope imaging, simultaneous, photon energy recovery technique, 1504(ab)
Duodenogastric reflux, ^{99m}Tc tetrofosmin, myocardial SPECT, 193

E

Editor's page, 1, 59, 135, 171
Electroconvulsive therapy (ECT), cerebral blood flow changes during, ^{99m}Tc HMPAO brain SPECT, 1562(ab)
Epidemiology, for the nuclear medicine technologist, 143, 150
Epilepsy, ^{99m}Tc HMPAO SPECT, FDG PET and, localization, 1527(ab)
Extravasation, bone-imaging agent, ipsilateral lymph nodes secondary to, 154

F

Filtered backprojection (FBP), compared with OSEM
motion artifacts, 1579(ab)
pelvic bone scan, 1513(ab)
uniformity requirements for SPECT image reconstruction, 79
Fluoride-18 altanserin, metabolite assay, FDG PET, human plasma, 1561(ab)
Fluorodeoxyglucose (FDG)
axillary uptake, whole-body studies, injection protocol in, 1512(ab)
dose calibrator nonlinearity, error in dispensing, 1575(ab)
LAL inhibition testing, low pH range effects, 1610(ab)
PET
bowel wall inflammation, 1508(ab)
comparison with separate acquisition protocol, 1503(ab)
dual-time point imaging, pulmonary nodules, 1564(ab)
^{99m}Tc HMPAO SPECT and, epilepsy, 1527(ab)
oncology and cardiology in same patient, 1553(ab)
quantitative tumor analysis, 1589(ab)
uptake, glucose level, age and fasting effects, 1565(ab)
Food and Drug Administration (FDA), PET drugs, 173

G

Gallbladder disease, evaluation and management, gallbladder ejection fraction, 1602(ab)
Gamma camera, coincidence imaging with, 1514(ab)
G-Codes, for PET, 173
Glomerular filtration rate (GFR), determination, plasma sampling frequency and range, Excel Solver Model, 1568(ab)
Glucose metabolism, FDG SPECT for, myocardial viability, 1506(ab)

H

Hepatocellular cancer, infusing ^{90}Y therapspheres, technical aspects, 1566(ab)
High-performance liquid chromatography (HPLC), size exclusion, radiochemical purity assessment, 1569(ab)
Hospital Outpatient Prospective Payment System (HOPPS), PET and, 173
Hybrid camera
background resolution and system efficiency, various rebinning parameters, 1580(ab)
PET/SPECT, fractions of scatter and disturbing radiation, 1584(ab)
Hyperreactive airway disease, escalating dose of adenosine in, 1552(ab)

I

Image analysis, DICOM, MayoImageX Active X, 1577(ab)
Image processing, brain tissue classification, parametric analysis, 1578(ab)
Image reconstruction, SPECT, uniformity requirements for, 79
Inferoposterior artifact, minimum detectable defect thickness for SPECT, 183
Instrumentation
PET, introduction to, 4, 19
quality control and, SPECT in 2001, 12
Iodine-131
patients treated with, radiation exposure to family members, 1601(ab)
therapy, hospitalized patient, safety precautions with, 61
thyroid uptake, gamma camera with medium energy collimator, 1576(ab)
Iodine-123 β-CIT, diagnosis, Parkinson's disease, 1526(ab)

Iterative reconstruction, image fusion, abdomen and pelvis, SPECT, 1573(ab)

J

Joint Review Committee on Educational Programs in Nuclear Medicine Technology (JRCNMT), 53, 202

K

Kidney function
GFR determination, plasma sampling frequency and range, Excel Solver Model, 1568(ab)
^{99m}Tc absolute uptake, pediatric values at 2–4 hours, 22
Kidney transplantation, postoperative radionuclide renography for, drawbacks, 1567(ab)

L

Left ventricular ejection fraction, measurements, rest versus stress ^{99m}Tc tetrofosmin SPECT, 1502(ab)
Liver, idiopathic uptake of ^{99m}Tc MDP, bone scintigraphy, 32
Lower extremity, extraskeletal myxoid chondrosarcoma, localization of ^{99m}Tc HMDP, 84
Lymph nodes, ipsilateral, left hand, visualization of, 154
Lymphoscintigraphy
^{99m}Tc filtered sulfur colloid, chylothorax, 30
^{99m}Tc MIBI and, sentinel lymph node status in melanoma, 152
whole-body, with transmission scan, 1511(ab)

M

MAA kits, shortage of, ventilation/perfusion scanning, 1612(ab)
MRI, bone, localization of pain before spinal injection, 1606(ab)
Maximum likelihood expectation maximization, reconstruction with, median filtering after, 1587(ab)
Medical radiation workers, risk associated with, 137
Medicare, regulations and reimbursement for PET, 173
Melanoma, sentinel lymph node status in, ^{99m}Tc MIBI and lymphoscintigraphy, 152
Message from the President, 3, 60, 136, 172
Miraluma, use with dense breasts, adjunct to mammography, 1510(ab)
Monoclonal antibodies (MAb), radiochemical purity assessment, HPLC, 1569(ab)
Motion correction, tomographic myocardial perfusion imaging, 1611(ab)
Multimodality imaging, recurrent thyroid cancer patients, 1609(ab)
Myocardial perfusion imaging
SPECT
minimum detectable defect thickness for, 183
^{99m}Tc tetrofosmin duodenogastric reflux, 193
tomographic, method of motion correction, 1611(ab)
Myocardial viability, FDG SPECT, dextrose/insulin infusion *versus* oral glucose loading, 1506(ab)
Myxoid chondrosarcoma, extraskeletal, localization of ^{99m}Tc HMDP in, 84

N

Nuclear medicine
corporate, centralized management model, 40
epidemiology for the technologist, 143
Nuclear medicine images, making slides for, 46
Nuclear medicine technologists, qualification as educators, 159
Nuclear Medicine Technology Certification Board (NMTCB)
computerized certification examination, 37
report, 52, 87, 163, 201
Nuclear scintigraphy, thyroid measurements, in thyrotoxic patients, 1528(ab)

O

Occupational radiation exposure, risk associated with, 137
Ordered-subsets expectation maximization (OSEM)
compared with FBP
motion artifacts, 1579(ab)
pelvic bone scan, 1513(ab)
SPECT image reconstruction techniques, uniformity requirements for, 79
Osteomyelitis, digital subtraction technique for diagnosis, 1603(ab)

P

Parametric imaging, brain tissue classification, segmentation technique for, 1578(ab)
Parkinson's disease
diagnosis with ^{123}I β-CIT, 1526(ab)
movement disorders, altropane SPECT binding in, 1613(ab)
Partial volume effect, objects with similar axial diameter, 1581(ab)
Pediatric patients, ^{99m}Tc absolute uptake, 2–4 hours, 22
PET
activity quantification, 1582(ab)
dopamine transporter density, striatum, altropane in, 1563(ab)
^{18}F altanserin in, human plasma, 1561(ab)
FDG
bowel wall inflammation, 1508(ab)
brain, pre and post injection transmission measurement, 1588(ab)
oncology and cardiology in same patient, 1553(ab)
quality after general nuclear medicine scan with ^{99m}Tc, 1555(ab)
recurrent pheochromocytoma, 1560(ab)
hybrid cameras, fractions of scatter and disturbing radiation, 1584(ab)
instrumentation, introduction to, 4
isolator, design, for aseptic processing, 1574(ab)
mobile, technologist exposures on, 1523(ab)
regulatory and reimbursement environment, 173, 180
whole-body, disturbed viewing systems based on JAVA, 1583(ab)
Pheochromocytoma, recurrent, FDG PET imaging, 1560(ab)
Picture archiving computer system (PACS), PET image viewing, JAVA technology, 1583(ab)
Positrons, introduction to PET instrumentation, 4
Pulmonary nodules, dual time point imaging, FDG PET, 1564(ab)

Q

Quality control
external test, minimum detectable defect thickness for SPECT, 183
improved, ^{99m}Tc tetrofosmin, 1570(ab)
instrumentation and, SPECT in 2001, 12
Quantitative measurements, ^{99m}Tc absolute uptake, pediatric values at 2–4 hours, 22

R

Radiation biology, terminology and, basic review, 67, 76
Radiation exposure
communication of, 156
family members, patients treated with ^{131}I, 1601(ab)
reduction of, PET technologists, 1522(ab)
risk associated with, 137, 147
Radiation safety
accident
cytogenetic and immunological follow-up, 1558(ab)
workers in Iran,chromosome aberrations in peripheral blood lymphocytes, 1559(ab)
communicating exposure, 156
^{131}I therapy, hospitalized patient, 61, 74
risk for medical workers, 137
Radiation therapy
basic biology concepts, 67
patient precautions, hospitalized patient, 61
Radioactive contamination, packages from radiopharmacy, 1554(ab)
Radioisotopes, therapy doses, syringe fill station for, 1585(ab)
Radiolabeled antibody therapy, ^{131}I J591 versus ^{90}Y J591, radiation dosimetry, 1521(ab)
Radiopharmaceuticals
aseptic operations, design of PET isolator for, 1574(ab)
routine radiochemical purity, kit failures, 1572(ab)
Radiopharmacy, radioactive contamination in packages from, 1554(ab)
Rebinning parameters, effects on background resolution and system efficiency, hybrid camera, 1580(ab)
Reconstruction, median filtering after, maximum likelihood expectation maximization, 1587(ab)
Reimbursement, for PET, 173
Renal plasma flow, ^{99m}Tc MAG3 estimation, correlation of blood ERPF and, 1608(ab)
Renography
^{99m}Tc MAG3 bolus arrival, clearance estimates, 1525(ab)
radionuclide, after kidney transplant, drawbacks of, 1567(ab)

S

Salivary glands, scintigraphy, semiquantitative analysis for uptake and clearance, 1529(ab)
Scatter correction, scintimammography, 1519(ab)
Scintimammography, scatter correction for, 1519(ab)
Sentinel nodes
imaging
breast mapping studies, 1509(ab)
evaluation of postoperative specimens, 1517(ab)
status in melanoma, lymphoscintigraphy and ^{99m}Tc MIBI, 152
Slides, for nuclear medicine images, 46
Sodium iodide crystal, ongoing exposure to 511 keV photons and, hybrid PET system, 1515(ab)
SPECT
altropane, Parkinson's disease, 1613(ab)
bone, localization of pain before spinal injection, 1606(ab)
brain artifacts, with metallic cranioplasty, 189
image fusion, abdomen and pelvis, 1573(ab)
image reconstruction, uniformity requirements for, FBP and OSEM techniques, 79
instrumentation and quality control, in 2001, 12, 20
^{99m}Tc HMPAO, FDG PET and, epilepsy, 1527(ab)
myocardial perfusion
minimum detectable defect thickness, 183
^{99m}Tc tetrofosmin duodenogastric reflux, 193
Stochastic radiation, effects, 67
Sulfur colloid, filtered, lymphoscintigraphy in chylothorax, 30
Syringes, stability and storage, ^{99m}Tc HMPAO and ECD, 197

T

Technetium-99m
brain SPECT, artifacts with metallic cranioplasty, 189
general nuclear medicine scan with, FDG PET procedures after, 1555(ab)
routine radiochemical purity, kit failures, 1572(ab)
Technetium-99m DMSA
absolute uptake, pediatric values at 2–4 hours, 22
early evaluation, urinary tract infection, 1530(ab), **s**
Technetium-99m ECD, stabilized stored in syringes, 197
Technetium-99m filtered sulfur colloid, lymphoscintigraphy with, chylothorax, 30
Technetium-99m GSA, purity and stability, chromatographic method for evaluation, 1524(ab)
Technetium-99m HMDP, localization of, extraskeletal myxoid chondrosarcoma, 84
Technetium-99m HMPAO
brain SPECT, cerebral blood flow changes during ECT, 1562(ab)
stabilized, stored in syringes, 197
Technetium-99m MAG3
bolus arrival time, clearance estimates, 1525(ab)
camera-based estimation, correlation of blood ERPF, renal plasma flow, 1608(ab)
Technetium-99m MDP, idiopathic hepatic uptake, 32
Technetium-99m MIBI
acute rest myocardial perfusion imaging, coronary flow in, 1551(ab)
dipyridamole and adenosine with, cardiac imaging, 1501(ab)
lymphoscintigraphy and, sentinel lymph node status in melanoma, 152
Technetium-99m Neotect, imaging, solitary pulmonary nodules, 1607(ab)
Technetium-99m serum albumin, in-house preparation, 1571(ab)
Technetium-99m tetrofosmin
duodenogastric reflux on myocardial SPECT, ejection fraction and, 193
improved quality control, 1570(ab)
SPECT, rest *versus* stress left ventricular ejection fraction, 1502(ab)
Technologist News, 56, 88, 164, 205
Thyroid cancer
^{131}I radiation therapy, patient precautions, 61
recurrent, multimodality assessments in, 1609(ab)
Thyroid volume, measurements, in thyrotoxic patients, 1528(ab)
Transmission tomography, nonuniform and uniform correction, PET and SPECT, 1586(ab)

U

Ultrasonography, thyroid measurements, in thyrotoxic patients, 1528(ab)
Uniformity, SPECT image reconstruction, FBP and OSEM techniques, 79
Urinary tract infection, early evaluation, ^{99m}Tc DMSA, 1530(ab)

V

Ventilation/perfusion scanning, MAA kits for, emergent shortage for, 1612(ab)
Ventilation system, internal bacteria filter, ^{133}Xe contamination in, 1556(ab)

X

Xenon-133
contamination, ventilation system's internal bacteria filter, 1556(ab)
leakage, used and unused vials, 1557(ab)

Y

Yttrium-90, theraspheres, infusing into hepatocellular cancer, 1556(ab)

United States Postal Service

Statement of Ownership, Management, and Circulation

1. Publication Title	2. Publication Number	3. Filing Date
Journal of Nuclear Medicine Technology	9 6 6 5 - 0 0	10/1/01
4. Issue Frequency	5. Number of Issues Published Annually	6. Annual Subscription Price
Quarterly	four	$80 USA; $85 Canada & Pan Am; $90 elsewhere

7. Complete Mailing Address of Known Office of Publication (Not printer) (Street, city, county, state, and ZIP+4): 1850 Samuel Morse Drive, Reston, VA 20190-5316 — Contact Person: Melissa McKenna; Telephone: 703-708-9000 x1239

8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not printer): 1850 Samuel Morse Drive, Reston VA 20190-5316

9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not leave blank)

Publisher (Name and complete mailing address): Society of Nuclear Medicine, Inc. 1850 Samuel Morse Drive, Reston, VA 20190-5316

Editor (Name and complete mailing address): Beth Harkness, MS 1850 Samuel Morse Drive, Reston, VA 20190-5316

Managing Editor (Name and complete mailing address): Kira Mayrides 1850 Samuel Morse Drive, Reston, VA 20190-5316

10. Owner (Do not leave blank. If the publication is owned by a corporation, give the name and address of the corporation immediately followed by the names and addresses of all stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, give the names and addresses of the individual owners. If owned by a partnership or other unincorporated firm, give its name and address as well as those of each individual owner. If the publication is published by a nonprofit organization, give its name and address.)

Full Name	Complete Mailing Address
Society of Nuclear Medicine, Inc.	1850 Samuel Morse Drive, Reston, VA 20190

11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check box → ☒ None

Full Name	Complete Mailing Address

12. Tax Status (For completion by nonprofit organizations authorized to mail at nonprofit rates) (Check one)
The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes:
☐ Has Not Changed During Preceding 12 Months
☐ Has Changed During Preceding 12 Months (Publisher must submit explanation of change with this statement)

PS Form 3526, October 1999 (See Instructions on Reverse)

13. Publication Title: Journal of Nuclear Medicine Technology		14. Issue Date for Circulation Data Below: September 2001	
15.	Extent and Nature of Circulation	Average No. Copies Each Issue During Preceding 12 Months	No. Copies of Single Issue Published Nearest to Filing Date
a.	Total Number of Copies (Net press run)	7628	8317
b. Paid and/or Requested Circulation	(1) Paid/Requested Outside-County Mail Subscriptions Stated on Form 3541. (Include advertiser's proof and exchange copies)	6552	7412
	(2) Paid In-County Subscriptions Stated on Form 3541 (Include advertiser's proof and exchange copies)	0	0
	(3) Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Non-USPS Paid Distribution	0	0
	(4) Other Classes Mailed Through the USPS	0	0
c.	Total Paid and/or Requested Circulation (Sum of 15b. (1), (2), (3), and (4))	6552	7402
d. Free Distribution by Mail (Samples, complimentary, and other free)	(1) Outside-County as Stated on Form 3541	10	10
	(2) In-County as Stated on Form 3541	0	0
	(3) Other Classes Mailed Through the USPS	0	0
e.	Free Distribution Outside the Mail (Carriers or other means)	175	400
f.	Total Free Distribution (Sum of 15d. and 15e.)	185	410
g.	Total Distribution (Sum of 15c. and 15f)	6737	7812
h.	Copies not Distributed	1064	505
i.	Total (Sum of 15g. and h.)	7801	8317
j.	Percent Paid and/or Requested Circulation (15c. divided by 15g. times 100)	97.3%	94.8%

16. Publication of Statement of Ownership
☒ Publication required. Will be printed in the December 2001 issue of this publication. ☐ Publication not required.

17. Signature and Title of Editor, Publisher, Business Manager, or Owner: Melissa McKenna — Director of Publication — Date: 10/4/01

I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including multiple damages and civil penalties).

Instructions to Publishers